T cells engineered to target senescence (original) (raw)

Senescence is a hallmark of cellular ageing and contributes to many diseases. A new method enabling immune cells to target senescent cells might offer improved therapeutic options.

By

  1. Verena Wagner
    1. Verena Wagner is at the MRC London Institute of Medical Sciences, London W12 0NN, UK, and at the Institute of Clinical Sciences, Faculty of Medicine, Imperial College London.
  2. Jesús Gil
    1. Jesús Gil is at the MRC London Institute of Medical Sciences, London W12 0NN, UK, and at the Institute of Clinical Sciences, Faculty of Medicine, Imperial College London.

Senescence is a form of cellular stress response. In some circumstances it can be harmful, and efforts are under way to develop therapies that target senescent cells. Writing in Nature, Amor et al.1 describe a method that selectively removes senescent cells in mice.

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$29.99 / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Nature 583, 37-38 (2020)

doi: https://doi.org/10.1038/d41586-020-01759-x

References

  1. Amor, C. et al. Nature 583, 127–132 (2020).
    Article Google Scholar
  2. Gorgoulis, V. et al. Cell 179, 813–827 (2019).
    Article PubMed Google Scholar
  3. Baker, D. J. et al. Nature 530, 184–189 (2016).
    Article PubMed Google Scholar
  4. Kang, T.-W. et al. Nature 479, 547–551 (2011).
    Article PubMed Google Scholar
  5. Lim, W. A. & June, C. H. Cell 168, 724–740 (2017).
    Article PubMed Google Scholar
  6. Curovic, V. R. et al. Diabetes Care 42, 1112–1119 (2019).
    Article PubMed Google Scholar
  7. Quaglia, M., Musetti, C. & Cantaluppi, V. N. Engl. J. Med. 374, 890–891 (2016).
    Article PubMed Google Scholar
  8. Wang, L. & Bernards, R. Front. Med. 12, 490–495 (2018).
    Article PubMed Google Scholar
  9. Ovadya, Y. & Krizhanovsky, V. J. Clin. Invest. 128, 1247–1254 (2018).
    Article PubMed Google Scholar
  10. Brudno, J. N. & Kochenderfer, J. N. Blood 127, 3321–3330 (2016).
    Article PubMed Google Scholar
  11. Eggert, T. et al. Cancer Cell 30, 533–547 (2016).
    Article PubMed Google Scholar
  12. Kim, K. M. et al. Genes Dev. 31, 1529–1534 (2017).
    Article PubMed Google Scholar
  13. Frescas, D. et al. Proc. Natl Acad. Sci. USA 114, E1668–E1677 (2017).
    Article PubMed Google Scholar

Download references

Competing Interests

J.G. has acted as a consultant for Unity Biotechnology, Geras Bio and Merck KGaA; owns equity in Unity Biotechnology and Geras Bio and is a named inventor in an MRC patent related to senolytic therapies.

Subjects

Latest on: